{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:03:37Z","timestamp":1774983817882,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1038\/ki.2013.38","type":"journal-article","created":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T08:57:27Z","timestamp":1367312247000},"page":"785-787","source":"Crossref","is-referenced-by-count":15,"title":["Synthetic oleanane triterpenoids: magic bullets or not?"],"prefix":"10.1016","volume":"83","author":[{"given":"Hanna E.","family":"Abboud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2013.38_bb0010","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.38_bb0015","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1124\/pr.111.004846","article-title":"Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease","volume":"64","author":"Liby","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1038\/ki.2013.38_bb0020","first-page":"CD008176","article-title":"Antioxidants for chronic kidney disease","volume":"10","author":"Jun","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1038\/ki.2013.38_bb0025","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.2337\/db11-0807","article-title":"Therapeutic potential of Nrf2 activators instreptozotocin-induced diabetic nephropathy","volume":"60","author":"Zheng","year":"2011","journal-title":"Diabetes"},{"key":"10.1038\/ki.2013.38_bb0030","first-page":"1746","article-title":"Bardoxolone methyl, chronic kidney disease, and type 2 diabetes","volume":"365","author":"Upadhyay","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.38_bb0035","first-page":"1746","article-title":"Bardoxolone methyl, chronic kidney disease, and type 2 diabetes","volume":"365","author":"McMahon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.38_bb0040","doi-asserted-by":"publisher","first-page":"H1320","DOI":"10.1152\/ajpheart.01118.2010","article-title":"Heme oxygenase metabolites inhibit tubuloglomerular feedback in vivo","volume":"300","author":"Wang","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1038\/ki.2013.38_bb0045","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1681\/ASN.2012050457","article-title":"Bardoxolone methyl decreases megalin and activates nrf2 in the kidney","volume":"23","author":"Reisman","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.38_bb0050","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/ki.2012.393","article-title":"The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II\u2013induced contraction of glomerular mesangial cells","volume":"83","author":"Ding","year":"2013","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.38_bb0055","series-title":"Am J Physiol Renal Physiol","article-title":"Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects","author":"Zoja","year":"2012"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815558493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815558493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T07:55:21Z","timestamp":1539676521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815558493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0085253815558493"],"URL":"https:\/\/doi.org\/10.1038\/ki.2013.38","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}